Cargando…

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: direct oral anticoagulants (DOACs) are a well-known alternative to conventional antagonist of vitamin-K (avK) and have emerged as the preferred choice due to their safety and efficacy profile. However, immune modulating drugs as cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, F, Casanova, A, Simone, S, Pellegrino, P L, D'arienzo, G, Brunetti, N D, Pesce, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	10.5.1 - Oral Anticoagulation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207264/ http://dx.doi.org/10.1093/europace/euad122.211

Ejemplares similares

Impact of concomitant proton pump inhibitor during oral anticoagulant treatment
por: Lee, K N, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Long-term effectiveness and safety of non-vitamin K antagonist anticoagulant in real world practice
por: Roh, S Y, et al.
Publicado: (2023)

Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation or left sided atrial tachycardia in patients on oral anticoagulation
por: Maslova, V, et al.
Publicado: (2023)

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study
por: Lehto, M, et al.
Publicado: (2023)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

Identification of a real-world clinical model associated with atrial fibrillation in a large french primary care database
por: Sabouret, S P F, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related strokes and mortality
por: Kang, D S, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related bleeding and mortality
por: Kang, D S, et al.
Publicado: (2023)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Implementation of In-Clinic SARS-CoV-2 Vaccination in Advanced Heart Failure, Lung Disease, and Transplant Clinic
por: Mathai, S.K., et al.
Publicado: (2022)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Suivi de la réponse sérologique au virus SARS-CoV-2 chez des professionnels de santé d'un centre de lutte contre le cancer dans un contexte de pandémie de COVID19 (PRO-SERO-COV)
por: Cantarel, C., et al.
Publicado: (2022)

Les inhibiteurs du système rénine-angiotensine et la mortalité par COVID-19 : une cohorte prospective de 1160 patients hypertendus, et revue de littérature
por: Gault, N., et al.
Publicado: (2021)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Gestion du don de sang lors de la pandémie SARS-CoV-2
por: Rekik, Taicr, et al.
Publicado: (2021)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era
por: Heng, Cai, et al.
Publicado: (2020)

Employeurs désorientés par la pandémie : les IDEST prennent contact
por: Colinet, Pascale, et al.
Publicado: (2022)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation
por: Mani, Helen, et al.
Publicado: (2015)

New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery
por: Serrano-Sánchez, Víctor, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u1o49k9pvdd1f32to33f3l2dja